Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756818 · ClinicalTrials.gov registry record · Phase 1
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03756818: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03756818 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03756818, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This phase I trial studies the best dose and side effects of TAK-659 and paclitaxel in treating patients with advanced solid tumors. TAK-659 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TAK-659 and paclitaxel may work better in treating patients with advanced solid tumors.
Interventions
- DRUG Paclitaxel
- OTHER Pharmacokinetic Study
- DRUG Mivavotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-03-05 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03756818
The ClinicalTrials.gov registry entry for NCT03756818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT03756818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03756818 about?
NCT03756818 is a clinical study titled "TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors". This phase I trial studies the best dose and side effects of TAK-659 and paclitaxel in treating patients with advanced solid tumors. TAK-659 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different wa...
What is the current status of trial NCT03756818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-03-05. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT03756818?
The interventions under investigation include: Paclitaxel (DRUG), Pharmacokinetic Study (OTHER), Mivavotinib (DRUG).
Who is sponsoring clinical trial NCT03756818?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.